OmniActive Health Technologies (OmniActive) has announced new clinical research demonstrating that Capsimax, its branded Capsicum annuum extract delivering capsaicinoids, supports natural GLP-1 activity while improving exercise performance and resting energy expenditure.
The findings, published in the Academic Journal of Sports Science & Medicine (AJSSM), provide direct clinical evidence supporting the ingredient's activity in natural GLP-1 pathways.
The study
The randomised clinical study evaluated 100 mg of Capsimax (two per cent capsaicinoids) in resistance-trained males during a seven-day supplementation period, with endpoints including exercise performance, resting energy expenditure (REE) and a GLP-1 outcome.
Key results include the following:
- approximately a 13% increase in GLP-1 levels following seven days of supplementation
- significant increase in REE, exceeding +120 kcal/day on both day one and day seven
- enhanced exercise performance and intensity, including increased peak force, rate of force development and higher peak and average power output after taking Capsimax
"These results mark an important evolution for Capsimax as a multi-dimensional ingredient," said Abhijeet Morde, Divisional VP, In vitro Biology, Animal Studies and Clinicals at OmniActive.
The study reinforces our ability to support consumers who are focused on sustainable weight wellness, whether they're seeking non-pharmaceutical options, complementing lifestyle changes, or prioritising energy and performance as part of long-term maintenance.
Why this matters
As GLP-1 pharmaceuticals reshape weight management, consumer interest is shifting towards lifestyle-friendly, affordable and natural products that enhance metabolic health and support long-term weight maintenance.
This new clinical data underscores Capsimax's importance across several categories, including natural GLP-1 support supplements, weight wellness formulations and performance-focused sports nutrition products.
The ingredient has already been evaluated in six prior human clinical studies, demonstrating benefits in metabolism support, appetite management and lipolysis (fat breakdown).
This latest research adds a new layer of differentiation by validating its role in supporting natural GLP-1 activity.
"Our findings highlight what truly differentiates Capsimax from traditional capsaicin-based ingredients," added Kratika Gupta, Senior VP, Global Marketing at OmniActive.
Capsimax delivers thermogenic and metabolic benefits in a way that is effective, well-tolerated and suitable for everyday use — without the harsh sensory effects that have historically limited capsaicin's broader adoption.
"This allows brands to unlock capsaicin's benefits in a more consumer-friendly, scalable format."
For formulators and manufacturers, Capsimax's low 100 mg dose, non-stimulant profile and experiential thermogenic effect make it well-suited for solutions that prioritise efficacy and consumer experience.
OmniActive added that the ingredient is commercially available and designed for seamless integration across a wide range of dietary supplement formats, including capsules, tablets and dry beverage powders.